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Introduction
Patients with autoinflammatory diseases or chronically
active autoimmune disease are at risk for developing
AA-type amyloidosis (AA).
Objectives
To identify risk factors for AA in patients with familial
Mediterranean fever and chronic inflammatory autoim-
mune diseases living in Germany.
Methods
Seventy-three patients with FMF and 39 patients with
active systemic inflammation due to autoimmune or idio-
pathic inflammation were evaluated in our reference center
for amyloidosis. Mutations in MEFV and the SAA-1 exon
3 variants were analyzed for their contribution to AA risk.
Amyloidosis was detected in all cases by congo red staining
of kidney or bowel biopsy specimens and AA was classified
by immunohistochemistry.
Results
Thirteen patients with FMF (18%) had AA which was
diagnosed either before their first contact or during the
initial presentation in our center. The relative risk (RR) for
amyloidosis of two M694V mutations was 1.15, compared
to a RR of 1.00 for a single M694V substitution and a RR
of 0.46 in the absence of a M694V mutation in these
patients. However, a homozygous SAA 1.1 genotype had a
RR of 3.65 (p=0.003), compared to a SAA RR of 0.63 for
SAA 1.1+other and to a RR of 0.32 for SAA other+other.
FMF patients with AA were older at FMF diagnosis (31 vs
23 years, p=0.003), and AA was diagnosed at a median age
of 34 years (95%CI 28.6-47.3). The delay of FMF diagnosis
was 17 years in patients with AA and 9 years in patients
without (p=0.064).
Twenty-three patients with rheumatic diseases or idio-
pathic inflammation had AA. A control group of 16
patients with chronically active systemic inflammation was
recruited from consecutive patients in our rheumatology
department. Twenty-two of 23 patients with AA (96%)
had the SAA1.1+1.1 genotype compared to 5 of 16
patients (31%) in the control group, resulting in a RR of
2.05 for AA (p=0.054). Within this group, 7 patients with
idiopathic inflammation could not be associated with any
autoimmune or autoinflammatory disorder and were con-
sidered to be idiopathic AA. These patients with idiopathic
AA were older at the onset of inflammation (51.0 vs 25.5
years, p=0.17) and were older at AA diagnosis (63.0 vs
53.5 years, p=0.9), but had a shorter duration of inflamma-
tion to AA diagnosis (16.0 vs 20.0 years, p=0.19).
Conclusion
Our data show that the SAA1.1+1.1 genotype is associated
with a higher risk for AA than homozygosity for the pyrin
M694V mutation. Although M694V+M694V is associated
with a more severe disease course, our data show that
SAA1.1+1.1 is the major risk factor for AA. In patients
with chronically rheumatic diseases or idiopathic AA,
homozygosity for SAA1.1 carries a RR of 3.65. Determina-
tion of the SAA polymorphism could be useful to assess
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